{"id":2154,"date":"2025-08-23T11:06:15","date_gmt":"2025-08-23T08:06:15","guid":{"rendered":"https:\/\/www.technology-asgard.com\/?p=2154"},"modified":"2025-08-23T11:06:17","modified_gmt":"2025-08-23T08:06:17","slug":"neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis","status":"publish","type":"post","link":"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/","title":{"rendered":"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis)"},"content":{"rendered":"\n<p><strong><br><\/strong><br><br>Author &#8211; Denys Pavlovich Sukhachov<\/p>\n\n\n\n<p>Medication for frontotemporal dementia<\/p>\n\n\n\n<p><strong><br>Design, Synthesis, and Therapeutic Potential of a Hybrid Rapamycin-Tetrahydrocannabinol (THC) Conjugate for Targeted Therapy<\/strong><\/p>\n\n\n\n<p><strong>1. Introduction<\/strong><\/p>\n\n\n\n<p>Rapamycin (sirolimus) and tetrahydrocannabinol (THC) are two bioactive compounds with distinct pharmacological properties:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapamycin<\/strong>: An mTOR inhibitor used as an immunosuppressant and anticancer agent.<\/li>\n\n\n\n<li><strong>THC<\/strong>: A CB1\/CB2 receptor agonist with anti-inflammatory, analgesic, and potential antitumor effects.<\/li>\n<\/ul>\n\n\n\n<p>Combining these molecules into a&nbsp;<strong>hybrid conjugate<\/strong>&nbsp;could enhance therapeutic synergy, reduce toxicity, and improve targeted delivery. This article explores:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular design<\/strong>&nbsp;(linker selection, modification sites).<\/li>\n\n\n\n<li><strong>Synthesis strategies<\/strong>&nbsp;(organic chemistry, chemical biology).<\/li>\n\n\n\n<li><strong>Potential applications<\/strong>&nbsp;(oncology, neurodegenerative diseases).<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>2. Molecular Design of the Conjugate<\/strong><\/p>\n\n\n\n<p><strong>2.1. Modification Sites<\/strong><\/p>\n\n\n\n<p><strong>For Rapamycin<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C40-hydroxyl group<\/strong>&nbsp;\u2013 Commonly modified (e.g., in temsirolimus).<\/li>\n\n\n\n<li><strong>C28-keto group<\/strong>&nbsp;\u2013 Can be reduced to OH for conjugation.<\/li>\n<\/ul>\n\n\n\n<p><strong>For THC<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Carboxylic acid group<\/strong>&nbsp;(if converted to THC-COOH).<\/li>\n\n\n\n<li><strong>Hydroxyl group<\/strong>&nbsp;(e.g., 11-OH-THC).<\/li>\n<\/ul>\n\n\n\n<p><strong>2.2. Linker Selection<\/strong><\/p>\n\n\n\n<p>The linker must:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Remain stable in circulation.<\/li>\n\n\n\n<li>Cleave controllably in target tissues (e.g., tumor microenvironment).<\/li>\n<\/ul>\n\n\n\n<p><strong>Linker Options<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Linker Type<\/strong><\/td><td><strong>Example<\/strong><\/td><td><strong>Pros<\/strong><\/td><td><strong>Cons<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Ester<\/strong><\/td><td>Rap\u2013O\u2013CO\u2013THC<\/td><td>Simple synthesis<\/td><td>Plasma instability<\/td><\/tr><tr><td><strong>Disulfide<\/strong><\/td><td>Rap\u2013S\u2013S\u2013THC<\/td><td>Cleaves under oxidative stress (e.g., in tumors)<\/td><td>Requires SH-modification<\/td><\/tr><tr><td><strong>Peptide<\/strong><\/td><td>Rap\u2013GFLG\u2013THC<\/td><td>Tumor protease-specific<\/td><td>Potential immunogenicity<\/td><\/tr><tr><td><strong>PEG spacer<\/strong><\/td><td>Rap\u2013PEG4\u2013THC<\/td><td>Improves solubility<\/td><td>May reduce activity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>3. Synthesis Strategy<\/strong><\/p>\n\n\n\n<p><strong>3.1. THC Derivative Synthesis<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>THC-COOH preparation<\/strong>:<ol><li>React THC with succinic anhydride (DMAP catalyst).<\/li><\/ol>\n<ol class=\"wp-block-list\">\n<li>Purify via column chromatography.<\/li>\n<\/ol>\n<\/li>\n\n\n\n<li><strong>Carboxyl group activation<\/strong>:\n<ol class=\"wp-block-list\">\n<li>Convert to NHS ester (EDC\/NHS).<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n\n\n\n<p><strong>3.2. Rapamycin Modification<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Introducing a thiol (\u2013SH) group<\/strong>:<ol><li>Replace C40\u2013OH with \u2013SH via mesylate (MsCl \u2192 NaSH).<\/li><\/ol>\n<ol class=\"wp-block-list\">\n<li>Alternative: Use heterobifunctional linkers (e.g., SMCC).<\/li>\n<\/ol>\n<\/li>\n\n\n\n<li><strong>Conjugation with THC<\/strong>:<ol><li><strong>Disulfide linker<\/strong>: Oxidize SH groups (H\u2082O\u2082 or air).<\/li><\/ol>\n<ol class=\"wp-block-list\">\n<li><strong>Peptide linker<\/strong>: Solid-phase synthesis (Fmoc chemistry).<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n\n\n\n<p><strong>3.3. Purification &amp; Characterization<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HPLC<\/strong>&nbsp;(high-performance liquid chromatography).<\/li>\n\n\n\n<li><strong>Mass spectrometry<\/strong>&nbsp;(MALDI-TOF).<\/li>\n\n\n\n<li><strong>NMR<\/strong>&nbsp;(structural confirmation).<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>4. Mechanism of Action &amp; Applications<\/strong><\/p>\n\n\n\n<p><strong>4.1. Oncology<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual targeting of mTOR and endocannabinoid systems<\/strong>:<ul><li>Rapamycin blocks cell proliferation.<\/li><\/ul>\n<ul class=\"wp-block-list\">\n<li>THC induces apoptosis via CB1\/CB2.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Controlled release<\/strong>: Disulfide linkers cleave in high-ROS tumor environments.<\/li>\n<\/ul>\n\n\n\n<p><strong>4.2. Neuroprotection<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alzheimer\u2019s disease<\/strong>:<ul><li>Rapamycin reduces tau aggregation.<\/li><\/ul>\n<ul class=\"wp-block-list\">\n<li>THC suppresses neuroinflammation via CB2.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p><strong>4.3. Reduced Toxicity<\/strong><\/p>\n\n\n\n<p>Conjugation may mitigate rapamycin\u2019s immunosuppressive effects via localized release.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>5. Challenges &amp; Future Directions<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bioavailability<\/strong>: Hydrophobicity may require nanoformulations (e.g., lipid nanoparticles).<\/li>\n\n\n\n<li><strong>Legal considerations<\/strong>: THC use requires regulatory approvals.<\/li>\n\n\n\n<li><strong>In vivo testing<\/strong>: Animal studies needed for pharmacokinetics.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>6. Conclusion<\/strong><\/p>\n\n\n\n<p>The&nbsp;<strong>rapamycin-THC conjugate<\/strong>&nbsp;is a promising approach for combination therapy. Optimal linkers (e.g., disulfide or peptide) enable selective release in target tissues. Future work should focus on:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Synthesis optimization,<\/li>\n\n\n\n<li>Preclinical trials,<\/li>\n\n\n\n<li>Delivery systems (nanocarriers).<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>References<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><em>Nature Reviews Drug Discovery<\/em>&nbsp;(2023) \u2013 mTOR inhibitors.<\/li>\n\n\n\n<li><em>Journal of Medicinal Chemistry<\/em>&nbsp;(2022) \u2013 Hybrid drug design.<\/li>\n\n\n\n<li>Patent US20180028577 \u2013 Rapamycin conjugates.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Author &#8211; Denys Pavlovich Sukhachov Medication for frontotemporal dementia Design, Synthesis, and Therapeutic Potential of a Hybrid Rapamycin-Tetrahydrocannabinol (THC) Conjugate for Targeted Therapy 1. Introduction Rapamycin (sirolimus) and tetrahydrocannabinol (THC) are two bioactive compounds with distinct pharmacological properties: Combining these molecules into a&nbsp;hybrid conjugate&nbsp;could enhance therapeutic synergy, reduce toxicity, and improve targeted delivery. This article explores: 2. Molecular Design of the Conjugate 2.1. Modification Sites For Rapamycin: For THC: 2.2. Linker Selection The linker must: Linker Options: Linker Type Example [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-2154","post","type-post","status-publish","format-standard","hentry","category-medical-research"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis) - Asgard Technology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis) - Asgard Technology\" \/>\n<meta property=\"og:description\" content=\"Author &#8211; Denys Pavlovich Sukhachov Medication for frontotemporal dementia Design, Synthesis, and Therapeutic Potential of a Hybrid Rapamycin-Tetrahydrocannabinol (THC) Conjugate for Targeted Therapy 1. Introduction Rapamycin (sirolimus) and tetrahydrocannabinol (THC) are two bioactive compounds with distinct pharmacological properties: Combining these molecules into a&nbsp;hybrid conjugate&nbsp;could enhance therapeutic synergy, reduce toxicity, and improve targeted delivery. This article explores: 2. Molecular Design of the Conjugate 2.1. Modification Sites For Rapamycin: For THC: 2.2. Linker Selection The linker must: Linker Options: Linker Type Example [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/\" \/>\n<meta property=\"og:site_name\" content=\"Asgard Technology\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-23T08:06:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-23T08:06:17+00:00\" \/>\n<meta name=\"author\" content=\"Asgard Technology\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Asgard Technology\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/\",\"url\":\"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/\",\"name\":\"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis) - Asgard Technology\",\"isPartOf\":{\"@id\":\"https:\/\/www.technology-asgard.com\/#website\"},\"datePublished\":\"2025-08-23T08:06:15+00:00\",\"dateModified\":\"2025-08-23T08:06:17+00:00\",\"author\":{\"@id\":\"https:\/\/www.technology-asgard.com\/#\/schema\/person\/7a9fadfd46fd8502fd6a6bb8371d0a19\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0413\u043e\u043b\u043e\u0432\u043d\u0430\",\"item\":\"https:\/\/www.technology-asgard.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.technology-asgard.com\/#website\",\"url\":\"https:\/\/www.technology-asgard.com\/\",\"name\":\"Asgard Technology\",\"description\":\"Asgard for a better future\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.technology-asgard.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.technology-asgard.com\/#\/schema\/person\/7a9fadfd46fd8502fd6a6bb8371d0a19\",\"name\":\"Asgard Technology\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.technology-asgard.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.technology-asgard.com\/wp-content\/uploads\/2024\/12\/sloj-4.svg\",\"contentUrl\":\"https:\/\/www.technology-asgard.com\/wp-content\/uploads\/2024\/12\/sloj-4.svg\",\"caption\":\"Asgard Technology\"},\"sameAs\":[\"https:\/\/www.technology-asgard.com\"],\"url\":\"https:\/\/www.technology-asgard.com\/en\/author\/asgard_0727\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis) - Asgard Technology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/","og_locale":"en_US","og_type":"article","og_title":"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis) - Asgard Technology","og_description":"Author &#8211; Denys Pavlovich Sukhachov Medication for frontotemporal dementia Design, Synthesis, and Therapeutic Potential of a Hybrid Rapamycin-Tetrahydrocannabinol (THC) Conjugate for Targeted Therapy 1. Introduction Rapamycin (sirolimus) and tetrahydrocannabinol (THC) are two bioactive compounds with distinct pharmacological properties: Combining these molecules into a&nbsp;hybrid conjugate&nbsp;could enhance therapeutic synergy, reduce toxicity, and improve targeted delivery. This article explores: 2. Molecular Design of the Conjugate 2.1. Modification Sites For Rapamycin: For THC: 2.2. Linker Selection The linker must: Linker Options: Linker Type Example [&hellip;]","og_url":"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/","og_site_name":"Asgard Technology","article_published_time":"2025-08-23T08:06:15+00:00","article_modified_time":"2025-08-23T08:06:17+00:00","author":"Asgard Technology","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Asgard Technology","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/","url":"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/","name":"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis) - Asgard Technology","isPartOf":{"@id":"https:\/\/www.technology-asgard.com\/#website"},"datePublished":"2025-08-23T08:06:15+00:00","dateModified":"2025-08-23T08:06:17+00:00","author":{"@id":"https:\/\/www.technology-asgard.com\/#\/schema\/person\/7a9fadfd46fd8502fd6a6bb8371d0a19"},"breadcrumb":{"@id":"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.technology-asgard.com\/en\/neurorapa-medication-for-frontotemporal-dementia-invented-as-soon-as-he-learned-about-bruce-willis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0413\u043e\u043b\u043e\u0432\u043d\u0430","item":"https:\/\/www.technology-asgard.com\/en\/"},{"@type":"ListItem","position":2,"name":"NeuroRapa- Medication for frontotemporal dementia (invented as soon as he learned about Bruce Willis)"}]},{"@type":"WebSite","@id":"https:\/\/www.technology-asgard.com\/#website","url":"https:\/\/www.technology-asgard.com\/","name":"Asgard Technology","description":"Asgard for a better future","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.technology-asgard.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.technology-asgard.com\/#\/schema\/person\/7a9fadfd46fd8502fd6a6bb8371d0a19","name":"Asgard Technology","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.technology-asgard.com\/#\/schema\/person\/image\/","url":"https:\/\/www.technology-asgard.com\/wp-content\/uploads\/2024\/12\/sloj-4.svg","contentUrl":"https:\/\/www.technology-asgard.com\/wp-content\/uploads\/2024\/12\/sloj-4.svg","caption":"Asgard Technology"},"sameAs":["https:\/\/www.technology-asgard.com"],"url":"https:\/\/www.technology-asgard.com\/en\/author\/asgard_0727\/"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/posts\/2154"}],"collection":[{"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/comments?post=2154"}],"version-history":[{"count":1,"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/posts\/2154\/revisions"}],"predecessor-version":[{"id":2155,"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/posts\/2154\/revisions\/2155"}],"wp:attachment":[{"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/media?parent=2154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/categories?post=2154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.technology-asgard.com\/en\/wp-json\/wp\/v2\/tags?post=2154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}